MYCMI-6

MYCMI-6 (NSC354961) is a potent and selective endogenous MYC:MAX protein interactions inhibitor. MYCMI-6 blocks MYC-driven transcription and binds selectively to the MYC bHLHZip domain with a K d of 1.6 μM. MYCMI-6 inhibits tumor cell growth in a MYC-dependent manner (IC 50 In Vitro MYCMI-6 (NSC354961) (6.25?μM; 48 hours) selectively suppresses MYC-driven tumor cell growth with high efficacy. ? MYCMI-6 significantly inhibits growth of Burkitt’s lymphoma cells (Mutu, Daudi and ST486) - another classical example of a MYC-driven tumor, having translocations of MYC to one of the immunoglobulin loci - in a dose-dependent manner with an average GI 50 of 0.5?μM. Treatment of MCF7 cells with the MYCMI-6 for 24?hours significantly decreased MYC:MAX isPLA signals to 7%. Titration showed an IC 50 for inhibition of MYC:MAX of less than 1.5?μM for MYCMI-6 by isPLA. MYCMI-6 inhibits the MYC:MAX heterodimer formation with an IC 50 of 3.8?μM. MYCMI-6 efficiently inhibits anchorage-independent growth of MYCN -amplified neuroblastoma cells with GI 50 values of In Vivo MYCMI-6 (20?mg/kg; i.p.; daily for 1-2 weeks) induces massive apoptosis and reduces tumor cell proliferation, tumor microvasculature density and MYC:MAX interaction in a MYC-dependent xenograft tumor model . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: 6-8 weeks old athymic nude mice (bearing MYCN-amplified SK-N-DZ neuroblastoma cells) Dosage: 20 mg/kg body weight Administration: I.p.; daily for 1-2 weeks Result: A dramatic increase in the extension of apoptotic areas in the tumors and a significant increase in non-proliferative areas as determined by Ki67 staining in tumors. Form:Solid

No numbering system information yet

No physical and chemical property information yet

No safety information yet

No production method and use information yet

No upstream information yet

No downstream information yet

No related product information yet